Log in

Relevant bibliographies by topics / Acamprosat / Journal articles

To see the other types of publications on this topic, follow the link: Acamprosat.

Journal articles on the topic 'Acamprosat'

Author: Grafiati

Published: 4 June 2021

Last updated: 27 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Acamprosat.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kiefer, Falk, Holger Jahn, Rüdiger Holzbach, Peer Briken, Robert Stracke, and Klaus Wiedemann. "Die NALCAM-Studie: Wirksamkeit, Verträglichkeit, Outcome." SUCHT 49, no. 6 (2003): 342–51. http://dx.doi.org/10.1024/suc.2003.49.6.342.

Full text

Abstract:

Ziel: Vergleich der Effektivität und Verträglichkeit von Naltrexon und Acamprosat in der Rückfallprophylaxe bei Alkoholabhängigkeit. </P><P>Methodik: Doppelblinde, placebo-kontrollierte Studie. Einschluss von 160 Patienten nach stationärem Alkoholentzug. Behandlung mit Naltrexon, Acamprosat, Naltrexon plus Acamprosat vs. Placebo im Rahmen eines ambulanten Therapieprogramms. Analyse der Behandlungseffekte nach 12 Wochen und im Follow-up. </P><P>Ergebnisse: Naltrexon, Acamprosat und Kombinations

APA, Harvard, Vancouver, ISO, and other styles

2

Fuchs and Riebenfeld. "Acamprosat und psychosoziale Intervention." Praxis 91, no. 17 (2002): 735–42. http://dx.doi.org/10.1024/0369-8394.91.17.735.

Full text

Abstract:

105 patients présentant une forte dépendance à l'alcool et traités dans 13 centres de Suisse ont pris part à cette étude ouverte. Pendant une période de 24 semaines, le taux d'abstinence a été déterminé sous acamprosate utilisé dans le cadre de programmes psychothérapeutiques d'intervention établis, les médecins ayant le choix entre cinq procédés différents. En outre, un profil socio-démographique a été établi. Il a été procédé à un examen physique et des données touchant à la tolérance de l'acamprosate ont été récoltées. Il était de plus intéressant de vérifier si la qualité de vie se modifia

APA, Harvard, Vancouver, ISO, and other styles

3

Soyka, Michael. "Pharmakologische Rückfallprophylaxe der Alkoholabhängigkeit." Nervenheilkunde 40, no. 08 (2021): 628–35. http://dx.doi.org/10.1055/a-1513-9420.

Full text

Abstract:

ZUSAMMENFASSUNGNur wenige Substanzen sind als sogenannte Anti-Craving-Me-dikamente zur pharmakogestützten Rückfallprophylaxe der Alkoholabhängigkeit zugelassen. Dazu gehören das in Deutschland nicht mehr vertriebene Disulfiram, die Opioidantagonisten Naltrexon und Nalmefen sowie Acamprosat. Gerade für Acamprosat und Naltrexon ist die Evidenzbasierung recht gut, bei mäßiger, aber klinisch signifikanter Effizienz. Sie werden trotzdem selten eingesetzt. Interessante Substanzen mit klinischer Perspektive sind am ehesten Baclofen, Vareniclin und Gabapentin. Die klinischen Befunde und Perspektiven d

APA, Harvard, Vancouver, ISO, and other styles

4

Soyka, M., and W. Zieglgänsberger. "Rückfallprophylaxe der Alkoholabhängigkeit mit Acamprosat." Der Internist 40, no. 3 (1999): 330–36. http://dx.doi.org/10.1007/s001080050341.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Wiedemann, K., and F. Kiefer. "Zur differenziellen Indikationsstellung von Anti-Craving-Substanzen bei Alkoholabhängigkeit." Nervenheilkunde 23, no. 09 (2004): 521–26. http://dx.doi.org/10.1055/s-0038-1626417.

Full text

Abstract:

ZusammenfassungDie Wirksamkeit der medikamentösen Rückfallprophylaxe in der Behandlung der Alkoholabhängigkeit wurde insbesondere für Acamprosat und Naltrexon nachgewiesen. Dennoch ist unklar, inwieweit eine pharmakologische Behandlung unabhängig von der individuellen Charakteristik des behandelnden Patienten wirksam ist. So stellt sich die Frage nach differenzierten Indikationskriterien. Aktuelle Studienergebnisse geben Hinweise darauf, dass Symptome wie Angst, Depression, somatische Störungen und Suchtdruck, aber auch typologische Differenzierungen hilfreich sein können, die Wirksamkeit der

APA, Harvard, Vancouver, ISO, and other styles

6

Rychlik, R., B. Paschen, D. Kirchhoff, D. Daniel, T. Pfeil, and A. Kilburg. "Die adjuvante Arzneimitteltherapie der Alkoholkrankheit mit Acamprosat." DMW - Deutsche Medizinische Wochenschrift 126, no. 33 (2001): 899–904. http://dx.doi.org/10.1055/s-2001-16502.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Schönfeldt-Lecuona, C., and M. Gahr. "Acamprosat und Naltrexon als Kombinationstherapie bei Alkoholund Benzodiazepinabhängigkeit." Nervenheilkunde 32, no. 01/02 (2013): 54–57. http://dx.doi.org/10.1055/s-0038-1628472.

Full text

Abstract:

ZusammenfassungAcamprosat und Naltrexon sind etablierte Strategien zur pharmakologischen Rückfallprophylaxe bei Patienten mit Alkoholabhängigkeit. Obwohl die Kombination beider Substanzen bei dieser Indikation aufgrund pharmakodynamischer und -kinetischer Überlegungen eine sinnvolle Therapieoption darstellt, welche in klinischen Studien als effektiv und sicher beschrieben wurde, wird sie im klinischen Alltag selten eingesetzt. Wir berichten über eine erfolgreiche Behandlung von Acamprosat und Naltrexon bei einer Patientin mit einer schweren Alkohol-und Benzodiazepinabhängigkeit, welche unter d

APA, Harvard, Vancouver, ISO, and other styles

8

Gahr, M., M. A. Kölle, and C. Schönfeldt-Lecuona. "Rückfallprävention bei Alkoholabhängigkeit: Acamprosat und Naltrexon als kombinierte pharmakologische Strategie." Der Nervenarzt 84, no. 5 (2012): 584–89. http://dx.doi.org/10.1007/s00115-012-3633-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Engelhard, K., C. Werner, H. Lu, O. Möllenberg, W. Zieglgänsberger, and E. Kochs. "Der neuroprotektive Einfluss des Glutamat-Antagonisten Acamprosat nach experimenteller zerebraler Ischämie." Der Anaesthesist 49, no. 9 (2000): 816–21. http://dx.doi.org/10.1007/s001010070054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Gallinat, J., M. Soyka, S. Ufer, et al. "EEG and event related potentials as indicators of central neurophysiological effects of acamprosat." Biological Psychiatry 42, no. 1 (1997): 215S. http://dx.doi.org/10.1016/s0006-3223(97)87799-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Walter, Marc, and Gerhard A. Wiesbeck. "Pharmakotherapie von Abhängigkeits- und Entzugssyndromen." Therapeutische Umschau 66, no. 6 (2009): 449–57. http://dx.doi.org/10.1024/0040-5930.66.6.449.

Full text

Abstract:

Störungen durch psychotrope Substanzen umfassen im engeren Sinn die akute Intoxikation, den schädlichen Gebrauch, die Abhängigkeit sowie die Entzugssyndrome. Im erweiterten Sinn können komorbide psychische Störungen sowie somatische Folgeschäden auftreten. In der Akutbehandlung erfolgen zunächst die Entgiftung und der Entzug psychotroper Substanzen, anschließend dienen die medikamentöse Rückfallprophylaxe oder eine Substitutionsbehandlung zur Stabilisierung bei bestehender Abhängigkeitserkrankung. Die Pharmakotherapie ist neben den psychosozialen Therapien ein entscheidender Grundpfeiler in de

APA, Harvard, Vancouver, ISO, and other styles

12

Antonescu, Irina E., Maria Karlgren, Maria L. Pedersen, et al. "Acamprosate Is a Substrate of the Human Organic Anion Transporter (OAT) 1 without OAT3 Inhibitory Properties: Implications for Renal Acamprosate Secretion and Drug–Drug Interactions." Pharmaceutics 12, no. 4 (2020): 390. http://dx.doi.org/10.3390/pharmaceutics12040390.

Full text

Abstract:

Acamprosate is an anionic drug substance widely used in treating symptoms of alcohol withdrawal. It was recently shown that oral acamprosate absorption is likely due to paracellular transport. In contrast, little is known about the eliminating mechanism clearing acamprosate from the blood in the kidneys, despite the fact that studies have shown renal secretion of acamprosate. The hypothesis of the present study was therefore that renal organic anion transporters (OATs) facilitate the renal excretion of acamprosate in humans. The aim of the present study was to establish and apply OAT1 (gene pr

APA, Harvard, Vancouver, ISO, and other styles

13

Kiefer, F., F. Andersohn, C. Otte, K. Wolf, H. Jahn, and K. Wiedemann. "Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence." Acta Neuropsychiatrica 16, no. 5 (2004): 233–38. http://dx.doi.org/10.1111/j.0924-2708.2004.00093.x.

Full text

Abstract:

Background:There is growing evidence that pharmacological treatment with two of the best validated anticraving drugs, acamprosate and naltrexone, is efficacious in promoting abstinence in recently detoxified alcohol-dependent subjects.Objective:The stability of effects after termination of treatment remains to be answered, especially when combining both the drugs.Method:After detoxification, 160 alcohol-dependent subjects participated in a randomized, double-blind, placebo-controlled trial. Patients received naltrexone or acamprosate or a combination of naltrexone and acamprosate or placebo fo

APA, Harvard, Vancouver, ISO, and other styles

14

Overman, Gerald P., Christian J. Teter, and Sally K. Guthrie. "Acamprosate for the Adjunctive Treatment of Alcohol Dependence." Annals of Pharmacotherapy 37, no. 7-8 (2003): 1090–99. http://dx.doi.org/10.1345/aph.1c351.

Full text

Abstract:

OBJECTIVE: To review the literature related to the treatment of alcohol dependence with acamprosate, a synthetic compound structurally similar to the naturally occurring amino acid, homotaurine. DATA SOURCES: Primary literature and review articles were identified by MEDLINE search (1966–June 2003). Abstracts from recent meetings were also reviewed. DATA SYNTHESIS: Acamprosate has been marketed in 24 countries. Although the precise mechanism of acamprosate in the treatment of alcohol-dependent patients is unclear, it may restore the balance between inhibitory and excitatory neurotransmission in

APA, Harvard, Vancouver, ISO, and other styles

15

Mason, Barbara J., and Raymond L. Ownby. "Acamprosate for the Treatment of Alcohol Dependence: A Review of Double-Blind, Placebo-Controlled Trials." CNS Spectrums 5, no. 2 (2000): 58–69. http://dx.doi.org/10.1017/s1092852900012827.

Full text

Abstract:

AbstractAcamprosate (calcium acetyl-homotaurine) is a synthetic compound that crosses the blood-brain barrier and has a chemical structure similar to that of the naturally occurring amino acid neuromediators, homotaurine and γ-aminobu-tyric acid (GABA). Acamprosate appears to act primarily by restoring normal N-methyl-D-aspartate (NMDA) receptor tone in the glutamate system, and has been shown to have a specific dose-dependent effect on decreasing voluntary alcohol intake in animals with no effects on food and water consumption. The safety and efficacy of acamprosate in alcohol-dependent outpa

APA, Harvard, Vancouver, ISO, and other styles

16

Yahn, Stephanie L., Lucas R. Watterson, and M. Foster Olive. "Safety and Efficacy of Acamprosate for the Treatment of Alcohol Dependence." Substance Abuse: Research and Treatment 7 (January 2013): SART.S9345. http://dx.doi.org/10.4137/sart.s9345.

Full text

Abstract:

Acamprosate (calcium acetylhomotaurine) is an amino acid modulator that has displayed efficacy in some clinical trials in reducing craving and promoting abstinence in alcohol dependent patients following detoxification. While acamprosate is safe and generally well-tolerated, not all studies have demonstrated clinical efficacy that is superior to placebo. In addition, the precise neurochemical mechanisms of action of acamprosate have still not yet been identified. In this review, we summarize current clinical data on the safety, efficacy, and pharmacokinetic properties of acamprosate, as well t

APA, Harvard, Vancouver, ISO, and other styles

17

Doeppner, Thorsten R., Jens R. Pehlke, Britta Kaltwasser, et al. "The Indirect NMDAR Antagonist Acamprosate Induces Postischemic Neurologic Recovery Associated with Sustained Neuroprotection and Neuroregeneration." Journal of Cerebral Blood Flow & Metabolism 35, no. 12 (2015): 2089–97. http://dx.doi.org/10.1038/jcbfm.2015.179.

Full text

Abstract:

Cerebral ischemia stimulates N-methyl-D-aspartate receptors (NMDARs) resulting in increased calcium concentration and excitotoxicity. Yet, deactivation of NMDAR failed in clinical studies due to poor preclinical study designs or toxicity of NMDAR antagonists. Acamprosate is an indirect NMDAR antagonist used for patients with chronic alcohol dependence. We herein analyzed the therapeutic potential of acamprosate on brain injury, neurologic recovery and their underlying mechanisms. Mice were exposed to cerebral ischemia, treated with intraperitoneal injections of acamprosate or saline (controls)

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Acamprosate." Reactions Weekly &NA;, no. 1392 (2012): 5. http://dx.doi.org/10.2165/00128415-201213920-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Acamprosate." Drugs in R & D 3, no. 1 (2002): 13–18. http://dx.doi.org/10.2165/00126839-200203010-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Wilde, Michelle I., and Antona J. Wagstaff. "Acamprosate." Drugs 53, no. 6 (1997): 1038–53. http://dx.doi.org/10.2165/00003495-199753060-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;. "Acamprosate." Reactions Weekly &NA;, no. 400 (1992): 4. http://dx.doi.org/10.2165/00128415-199204000-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Foster, Rachel H., and Karen J. McClellan. "Acamprosate." PharmacoEconomics 16, no. 6 (1999): 743–55. http://dx.doi.org/10.2165/00019053-199916060-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Scott, Lesley J., David P. Figgitt, Susan J. Keam, and John Waugh. "Acamprosate." CNS Drugs 19, no. 5 (2005): 445–64. http://dx.doi.org/10.2165/00023210-200519050-00006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Acamprosate." Reactions Weekly &NA;, no. 1333 (2011): 7. http://dx.doi.org/10.2165/00128415-201113330-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

. "Acamprosaat." Medisch-Farmaceutische Mededelingen 36, no. 5 (1998): 115. http://dx.doi.org/10.1007/bf03057138.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kennedy, William Klugh, Megan Leloux, Eric C. Kutscher, Paul L. Price, Anne E. Morstad, and Ryan M. Carnahan. "Acamprosate." Expert Opinion on Drug Metabolism & Toxicology 6, no. 3 (2010): 363–80. http://dx.doi.org/10.1517/17425251003641975.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Pelc, I., P. Verbanck, O. Le Bon, M. Gavrilovic, K. Lion, and P. Lehert. "Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients." British Journal of Psychiatry 171, no. 1 (1997): 73–77. http://dx.doi.org/10.1192/bjp.171.1.73.

Full text

Abstract:

BackgroundAcamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions.MethodIn order to assess the efficacy and safety of the drug in the treatment of detoxified alcoholics, we performed a 90-day double-blind trial comparing two dosages of acamprosate (1332 mg/day and 1998 mg/day).ResultsFor all efficacy parameters, acamprosate appeared to be significantly superior to placebo, with a trend towards a better effect at the higher dosage. Furthermore, acamprosate appeared to be extremely safe.ConclusionThis study confirms that acampr

APA, Harvard, Vancouver, ISO, and other styles

28

Oldroyd, Christopher, Jonathan Wood, and Michael Allison. "Real-world analysis of acamprosate use in patients with cirrhosis and alcohol-associated hepatitis." BMJ Open Gastroenterology 11, no. 1 (2024): e001654. https://doi.org/10.1136/bmjgast-2024-001654.

Full text

Abstract:

ObjectivePreventing return to alcohol is of critical importance for patients with alcohol-related cirrhosis and/or alcohol-associated hepatitis. Acamprosate is a widely used treatment for alcohol use disorder (AUD). We assessed the impact of acamprosate prescription in patients with advanced liver disease on abstinence rates and clinical outcomes.MethodsThis was a retrospective case–control study. We reviewed data on all patients admitted to a large tertiary centre in the UK with alcohol-related cirrhosis and/or alcohol-associated hepatitis. We used propensity risk score matching to match pati

APA, Harvard, Vancouver, ISO, and other styles

29

Jbara, Jalal. "Comparison of Acamprosate and Naltrexone Treatment in Patients with Alcohol Use Disorder (AUD) for Relapse Prevention." New Medical Innovations and Research 5, no. 2 (2024): 01–03. https://doi.org/10.31579/2767-7370/089.

Full text

Abstract:

Alcohol use disorder (AUD) is a common disorder in the modern world. Interventions and treatments for AUD have not changed since 2010, using psychosocial interventions and medications such as acamprosate and naltrexone. The comparison between the effectiveness of acamprosate and naltrexone was conducted to provide the best option for relapse prevention and abstinence maintenance. The results were that some studies found that naltrexone was twice as effective as acamprosate in preventing relapses over a year. Others showed that acamprosate had better results in increasing the abstinence rate [O

APA, Harvard, Vancouver, ISO, and other styles

30

Baltieri, Danilo Antonio, and Arthur Guerra de Andrade. "Efficacy of acamprosate in the treatment of alcohol-dependent outpatients." Revista Brasileira de Psiquiatria 25, no. 3 (2003): 156–59. http://dx.doi.org/10.1590/s1516-44462003000300007.

Full text

Abstract:

OBJECTIVE: To evaluate the efficacy and security of acamprosate in the treatment of 75 men, aged 18 to 59 years, with diagnosis of alcohol dependence according to the ICD-10. METHODS: Double-blind, placebo-controlled study, 24-week long. After a one-week detoxification period, patients were randomly divided in two groups: the first group received acamprosate (six tablets of 333 mg/d for 12 weeks) and the second group received placebo (six tablets for 12 weeks). After the first 12 weeks, patients continued the follow-up for further 12 weeks without medication. RESULTS: Patients who were receivi

APA, Harvard, Vancouver, ISO, and other styles

31

Kesan, Akhil, Pranjal Dey, Sourav Khanra, Samiksha Singhai, and Monalisa Boro. "Low dose baclofen and standard dose acamprosate had comparable changes in brain glutamate, brain Gamma amino butyric acid (GABA) and craving among patients with alcohol dependence syndrome: A 1H-MRS based open label randomized study." Industrial Psychiatry Journal 34, no. 1 (2025): 25–31. https://doi.org/10.4103/ipj.ipj_187_23.

Full text

Abstract:

Background: Understanding of the mechanism of action of Baclofen as anticraving inalcohol dependence syndrome (ADS) is limited. Aim: Our study aimed to examine and compareearly changes in brain glutamate and GABA with Baclofen and Acamprosate among patients with alcohol dependence syndrome. Material and Methods: Forty patients with ADS were recruited with purposive sampling and were randomized into two groups using computer-generated randomization. At the end of detoxification (CIWA-Ar <10) brain glutamate and GABA were measured with proton magnetic resonance spectroscopy (1H-MRS) in the an

APA, Harvard, Vancouver, ISO, and other styles

32

Thorne, Joseph, and Sophie Quarshie. "Audit of appropriate consideration of anti-craving medication following alcohol detoxification in a north east addictions service." BJPsych Open 7, S1 (2021): S354. http://dx.doi.org/10.1192/bjo.2021.936.

Full text

Abstract:

AimsNICE guidelines recommend that all patients who undergo a successful alcohol detoxification programme should be considered for treatment with acamprosate or oral naltrexone. This audit studied the proportion of patients considered for acamprosate or naltrexone treatment in a North-East Addictions Service. Primary aimTo explore whether naltrexone/acamprosate had been considered for each patient completing alcohol detoxification.Secondary aims what proportion of those offered agreed to be prescribed acamprosate/naltrexonewhether these patients were being adequately followed up in terms of pr

APA, Harvard, Vancouver, ISO, and other styles

33

Farhadi, Mohammad, Mohammad Mahdi Salem, Alimohamad Asghari, Ahmad Daneshi, Marjan Mirsalehi, and Saeid Mahmoudian. "Impact of Acamprosate on Chronic Tinnitus: A Randomized-Controlled Trial." Annals of Otology, Rhinology & Laryngology 129, no. 11 (2020): 1110–19. http://dx.doi.org/10.1177/0003489420930773.

Full text

Abstract:

Objectives: Tinnitus is a common and distressing otologic symptom, with various probable pathophysiologic mechanisms, such as an imbalance between excitatory and inhibitory mechanisms. Acamprosate, generally used to treat alcoholism, is a glutaminergic antagonist and GABA agonist suggested for treating tinnitus. Thus, we aimed to evaluate the efficacy and safety of acamprosate in the treatment of tinnitus. Methods: The current randomized-controlled trial study included 20 subjects with chronic tinnitus. After performing psycho-acoustic, psychometric and electrophysiological evaluations, all st

APA, Harvard, Vancouver, ISO, and other styles

34

Singh, Samant, Lakhan Kataria, and Mohd Rashid Alam. "A comparative study evaluating the efficacy of naltrexone versus acamprosate as anticraving agents in alcohol use disorder." Industrial Psychiatry Journal 34, no. 1 (2025): 97–102. https://doi.org/10.4103/ipj.ipj_413_24.

Full text

Abstract:

Background: Alcohol use disorders (AUDs) are characterized by excessive alcohol consumption, negatively impacting health, social life, and economic status. Globally, AUD contributes to significant disease burden, causing millions deaths annually. Despite the availability of treatments, relapse rates remain high. Naltrexone and acamprosate, two FDA-approved anticraving agents, are widely used to prevent relapse. However, comparative studies in Indian populations are limited, prompting this study to assess the efficacy of these drugs in treating AUD. Aim: This study aimed to compare the effectiv

APA, Harvard, Vancouver, ISO, and other styles

35

Brager, Allison, Rebecca A. Prosser, and J. David Glass. "Acamprosate-responsive brain sites for suppression of ethanol intake and preference." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 301, no. 4 (2011): R1032—R1043. http://dx.doi.org/10.1152/ajpregu.00179.2011.

Full text

Abstract:

Acamprosate suppresses alcohol intake and craving in recovering alcoholics; however, the central sites of its action are unclear. To approach this question, brain regions responsive to acamprosate were mapped using acamprosate microimplants targeted to brain reward and circadian areas implicated in alcohol dependence. mPer2 mutant mice with nonfunctional mPer2, a circadian clock gene that gates endogenous timekeeping, were included, owing to their high levels of ethanol intake and preference. Male wild-type (WT) and mPer2 mutant mice received free-choice (15%) ethanol/water for 3 wk. The ethan

APA, Harvard, Vancouver, ISO, and other styles

36

Jadeja, Priyanka, Jaimin S. Patel, Dimal A. Shah, and Vandana B. Patel. "DEVELOPMENT OF LIQUID CHROMATOGRAPHIC METHOD FOR ESTIMATION OF ACAMPROSATE CALCIUM AND BACLOFEN COMBINATION USED IN TREATMENT OF NEUROLOGICAL DISORDERS." INDIAN DRUGS 58, no. 03 (2021): 54–58. http://dx.doi.org/10.53879/id.58.03.11346.

Full text

Abstract:

A specific, accurate, precise, and reproducible liquid chromatographic method has been developed and validated for the estimation of acamprosate calcium and baclofen in combination. The separation was achieved using stationary phase Phenomenex C18 column (150 mm× 4.6 mm.) in isocratic mode, with mobile phase containing 0.05 M potassium dihydrogen orthophosphate buffer (pH 7) : acetonitrile (10:90 V/V), at a flow rate of 1.0 mL/min and effluents were monitored at 210 nm. The retention time of acamprosate calcium and baclofen were found to be 1.9 min and 5.3 min, respectively. The linearity for

APA, Harvard, Vancouver, ISO, and other styles

37

Tolomeo, Serenella, and Alex Baldacchino. "Adherence to Prescribed Acamprosate in Alcohol Dependence and 1-Year Morbidities and Mortality: Utilizing a Data Linkage Methodology." Journal of Clinical Medicine 10, no. 10 (2021): 2102. http://dx.doi.org/10.3390/jcm10102102.

Full text

Abstract:

Objectives: We tested the hypothesis that poor adherence is associated with a greater risk of alcohol-caused mortality and morbidities within the first year of discontinuing this medication. Materials and Methods: A retrospective cohort study of 3319 individuals who received acamprosate in the East of Scotland in a 10-year period was conducted using a health informatics approach with record linkage of dispensing data, hospital utilization (SMR) and General Register Office of Scotland (GROS) data. The primary outcome was adherence between one to six months after initiating acamprosate medicatio

APA, Harvard, Vancouver, ISO, and other styles

38

Furlotti, Guido, Claudia Cavarischia, Alex Comely, et al. "A Convenient, Scalable Process for the Preparation and Purification of Calcium Acamprosate." Synthesis 52, no. 19 (2020): 2828–32. http://dx.doi.org/10.1055/s-0040-1707399.

Full text

Abstract:

Calcium acamprosate (Campral, N-acetylhomotaurine calcium salt) is a well-established drug for the treatment of alcohol dependence. Its preparation is generally based on a three-step process with some remarkable drawbacks. To avoid these flaws, we have developed a direct, scalable, one-pot procedure for the preparation of calcium acamprosate entailing the nucleophilic opening of readily available 1,3-propanesultone with potassium acetamide (from acetamide and potassium tert-butoxide) in N,N-dimethylformamide solution, followed by in situ cation exchange by addition of calcium chloride at contr

APA, Harvard, Vancouver, ISO, and other styles

39

Alho, H. "Disulfiram, Naltrexone and Acamprosate in the Treatment of Alcohol Dependence." European Psychiatry 24, S1 (2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70531-0.

Full text

Abstract:

Acamprosate, naltrexone and disulfiram have been shown to reduce drinking and/or improve abstinence. We performed a randomized, multicenter study in two phases; first, 12-week continuous supervised medication, followed by targeted medication up to 52 weeks in addition to a 67-week follow up period. 243 voluntary treatment-seeking alcohol-dependent adult outpatients were randomized 1:1:1 to receive supervised naltrexone, acamprosate or disulfiram, 50 mg, 1998 mg or 200 mg respectively per day and brief manual-based cognitive behavioral intervention. The primary outcome measures were the time to

APA, Harvard, Vancouver, ISO, and other styles

40

Raj, Y. Pritham. "Gambling on Acamprosate." Journal of Clinical Psychiatry 71, no. 09 (2010): 1245–46. http://dx.doi.org/10.4088/jcp.10l06059ecr.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Rees, Sharon. "Drug Breakdown: ACAMPROSATE." Journal of Prescribing Practice 6, no. 11 (2024): 446–47. http://dx.doi.org/10.12968/jprp.2024.0033.

Full text

Abstract:

In this column, Sharon Rees aims to refresh knowledge and interest in some of the commonly used drugs in a series of posts on X. This month she is talking about #acamprosate With the help of Prescribing and Therapeutics Training Ltd and the Journal of Prescribing Practice, you can earn your 1-hour CPD certificate

APA, Harvard, Vancouver, ISO, and other styles

42

Azevedo, Andréia A., and Ricardo R. Figueiredo. "Uso do acamprosato no tratamento do zumbido: um estudo duplo-cego." Revista Brasileira de Otorrinolaringologia 71, no. 5 (2005): 618–23. http://dx.doi.org/10.1590/s0034-72992005000500012.

Full text

Abstract:

O tratamento do zumbido é, ainda nos dias de hoje, um grande desafio para os otorrinolaringologistas. Várias lacunas persistem em sua fisiopatologia, tendo como resultado vários tipos de tratamento, com resultados muito irregulares. O acamprosato é uma droga utilizada no tratamento do alcoolismo, devido à sua ação reguladora da transmissão glutamatérgica e GABA-érgica, nunca tendo sido empregado no tratamento do zumbido. OBJETIVO: Avaliar a segurança e eficácia do uso do acamprosato, no tratamento do zumbido de causa neurossensorial. FORMA DE ESTUDO: ensaio clinico randomizado. MATERIAL E MÉTO

APA, Harvard, Vancouver, ISO, and other styles

43

Mukesh, Chandra Das, and Paul Minj Abhinav. "Acamprosate as the Remedial Molecule in Sensorineural Tinnitus." International Journal of Pharmaceutical and Clinical Research 15, no. 10 (2023): 1500–1504. https://doi.org/10.5281/zenodo.11304756.

Full text

Abstract:

<strong>Background:</strong> The management of tinnitus remains a significant clinical hurdle for otolaryngologists in the field. Numerous aspects pertaining to the pathophysiology of this condition still remain elusive, giving rise to a diverse array of therapeutic approaches, yielding inconsistent outcomes. Acamprosate, a pharmacological agent, is commonly employed in the therapeutic management of alcohol use disorder. This drug exerts its effects by modulating glutamatergic and GABAergic neurotransmission. Notably, acamprosate has not been previously utilised in the treatment of tinnit

APA, Harvard, Vancouver, ISO, and other styles

44

Saivin, Sylvie, Thierry Hulot, Sylvie Chabac, Adrian Potgieter, Philippe Durbin, and Georges Houin. "Clinical Pharmacokinetics of Acamprosate." Clinical Pharmacokinetics 35, no. 5 (1998): 331–45. http://dx.doi.org/10.2165/00003088-199835050-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Rösner, Susanne, Andrea Hackl-Herrwerth, Stefan Leucht, Philippe Lehert, Simona Vecchi, and Michael Soyka. "Acamprosate for alcohol dependence." Sao Paulo Medical Journal 128, no. 6 (2010): 379. http://dx.doi.org/10.1590/s1516-31802010000600014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Mason, Barbara J. "Acamprosate, Alcoholism, and Abstinence." Journal of Clinical Psychiatry 76, no. 02 (2015): e224-e225. http://dx.doi.org/10.4088/jcp.14com09632.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

&NA;. "Acamprosate Therapy for Alcoholism." Nurse Practitioner 30, no. 3 (2005): 62. http://dx.doi.org/10.1097/00006205-200503000-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Guzik, Patrycya, Lindey Bankes, and Thomas M. Brown. "Acamprosate and Primitive Reflexes." Annals of Pharmacotherapy 41, no. 4 (2007): 715–18. http://dx.doi.org/10.1345/aph.1h270.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Moore, N., and C. Libert. "Acamprosate, citalopram, and alcoholism." Lancet 337, no. 8751 (1991): 1228. http://dx.doi.org/10.1016/0140-6736(91)92903-f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Sass, Henning. "Relapse Prevention by Acamprosate." Archives of General Psychiatry 53, no. 8 (1996): 673. http://dx.doi.org/10.1001/archpsyc.1996.01830080023006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!